Angioplasty balloons coated with at least one limus drug, which may be in crystalline form, optionally with at least one excipient, and methods for manufacturing such coated angioplasty balloons.

Minimally invasive treatment methods for benign prostatic hyperplasia (BPH) tissue. A system includes a sustained release formulation comprising a cytostatic or cytotoxic drug, and an applicator or delivery system for local delivery of a composition comprising or consisting essentially of the sustained release formulation to the prostate. The applicator containing the composition is characterized by a KIR value of between 40 and 400 Centipoise per unit area.

There is disclosed a method of improving the reliability of coating an implantable medical device, such as a stent, with bioactive material in the absence of a carrier material such as a matrix or polymer layer. The method involves cleaning volatile components from the exposed surfaces of the medical device, removing carbon deposits and then applying a uniform carbon layer in a controlled environment. The deliberately applied carbon layer masks impurities of the underlying native oxide layer and leads to more uniform bioactive material coating not only a over the surfaces of a single medical device but also from device to device within a batch and between batches of devices. This improves production as well as optimising the amount and release of drug on the medical device without the need for a carrier material.

Implantable medical product, comprising a basic body and an imidazole derivative in the form of its free base; wherein said basic body has on its polymeric surface a layer containing the imidazole derivative as an active ingredient, which displays an antithrombogenic, antiproliferative, anti-inflammatory or antiadhesive effect, or a combination thereof.

Compositions, systems, devices, and methods for performing precise chemical treatment of tissues are disclosed. Systems, devices, and methods for administering a chemical agent to one or more a precise regions within a tissue mass are disclosed. Compositions, systems, devices, and methods for treating targeted regions within a tissue mass are disclosed. Systems, devices, and methods for identifying, localizing, monitoring neural traffic in the vicinity of, quantifying neural traffic in the vicinity of, and mapping neural traffic near targeted regions within a tissue mass are disclosed.

The present invention relates to microparticles that can be used as drug-loaded hydrogel particles for embolization and a method for manufacturing same. The microparticles of the present invention have a very excellent anticancer agent adsorption ability, a short anticancer agent adsorption time, and a controllable decomposition time when administered in vivo. Therefore, when the microparticles of the present invention are used in chemoembolization, not only the anticancer effect is excellent, but also side effects can be minimized.

A disposable device for treating a condition of a ureter or kidney having a cylindrical body about 1-2 mm in diameter by about 5 to 10 mm in length and having a top and bottom end. The body is made of absorbent material that expands upon contact with pharmaceutical agent and bodily fluids and includes a string connected to the bottom end of the body for removing the device. The device can be used to treat a condition of the ureter or kidney by inserting into the ureter or kidney, delivering a pharmaceutical agent, and removing the device after it has been impregnated with fluid. The device can be included in a kit with an insertion device and/or appropriate pharmaceutical agents.

The present disclosure relates to drug eluting stents, methods of making, using, and verifying long-term stability of the drug eluting stents, and methods for predicting long term stent efficacy and patient safety after implantation of a drug eluting stent. In one embodiment, a drug eluting stent may include a stent framework; a drug-containing layer; a drug embedded in the drug-containing layer; and a biocompatible base layer disposed over the stent framework and supporting the drug-containing layer. The drug-containing layer may have an uneven coating thickness. In addition or in alternative, the drug-containing layer may be configured to significantly dissolve/dissipateldisappear between 45 days and 60 days after stent implantation. Stents of the present disclosure may reduce, minimize, or eliminate patient risks associated with the implantation of a stent, including, for example, restenosis, thrombosis, and/or MACE.

Disclosed herein are elastic, bioresorbable encasements for medical implants, methods for making the same and uses thereof.

Microspheres, compositions including the microspheres, and methods of using the microspheres are disclosed herein. The microspheres can be substantially spherical and can include a copolymer of a monomer (such as an acrylic monomer) and a cyclodextrin or a derivative thereof. The microspheres can also include a therapeutic agent, such as a platinum-based drug.